Literature DB >> 29360942

IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis.

Chia-Hung Chou1, Chi-Sheng Hung2,3, Che-Wei Liao4, Lin-Hung Wei1, Ching-Way Chen5, Chia-Tung Shun6,7, Wen-Fen Wen7, Cho-Hua Wan8, Xue-Ming Wu9, Yi-Yao Chang10, Vin-Cent Wu2, Kwan-Dun Wu2, Yen-Hung Lin2.   

Abstract

Aims: An excess of aldosterone results in cardiac remodelling and fibrosis. Interleukin-6 (IL-6) is a key mediator in the fibrotic process; however, the effect of aldosterone on the expression of IL-6 remains unclear. We investigated whether aldosterone induces the expression of IL-6 and thereby contributes to the fibrotic process. Methods and results: In this clinical study, we prospectively enrolled 25 patients with primary aldosteronism (PA) and 26 patients with essential hypertension (EH). The PA patients had higher plasma IL-6 levels, left ventricular mass index, degree of myocardial fibrosis, and more impaired diastolic function than the EH patients. In addition, plasma IL-6 levels were positively correlated with 24-h urinary aldosterone and echocardiographic parameters. In cell studies, we investigated the possible molecular mechanism how aldosterone-induced IL-6 secretion and the further effects of collagen production. Aldosterone significantly induced IL-6 protein and mRNA production in human umbilical vein endothelial cells. Intracellular signalling occurred through the mineralocorticoid receptor/PI3K/Akt/NF-kB pathway. In cardiac fibroblasts, IL-6 trans-signalling played a critical role in aldosterone-induced IL-6-enhanced fibrosis-related factor expression. To further investigate the role of IL-6 trans-signalling in aldosterone-induced cardiac fibrosis, we measured the severity of myocardial fibrosis in aldosterone infusion mice models including an IL-6 chemical inhibitor and Sgp130 Knockin Transgenic Mice. Mice receiving recombinant soluble gp130 and Sgp130 Knockin Transgenic Mice prevented myocardial fibrosis and cardiac hypertrophy by aldosterone infusion. Conclusions: IL-6 trans-signalling contributes to aldosterone-induced cardiac fibrosis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29360942     DOI: 10.1093/cvr/cvy013

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  30 in total

Review 1.  Myocardial Injury in COVID-19 and Its Implications in Short- and Long-Term Outcomes.

Authors:  Andrea Izquierdo-Marquisá; Hector Cubero-Gallego; Álvaro Aparisi; Beatriz Vaquerizo; Núria Ribas-Barquet
Journal:  Front Cardiovasc Med       Date:  2022-05-26

Review 2.  Left ventricular remodeling and dysfunction in primary aldosteronism.

Authors:  Cheng-Hsuan Tsai; Chien-Ting Pan; Yi-Yao Chang; Zheng-Wei Chen; Vin-Cent Wu; Chi-Sheng Hung; Yen-Hung Lin
Journal:  J Hum Hypertens       Date:  2020-10-16       Impact factor: 3.012

Review 3.  Cardiac fibrosis.

Authors:  Nikolaos G Frangogiannis
Journal:  Cardiovasc Res       Date:  2021-05-25       Impact factor: 10.787

Review 4.  Reversion inducing cysteine rich protein with Kazal motifs and cardiovascular diseases: The RECKlessness of adverse remodeling.

Authors:  Jacob J Russell; Laurel A Grisanti; Scott M Brown; Chastidy A Bailey; Shawn B Bender; B Chandrasekar
Journal:  Cell Signal       Date:  2021-03-27       Impact factor: 4.850

5.  Influence of Different Treatment Strategies on New-Onset Atrial Fibrillation Among Patients With Primary Aldosteronism: A Nationwide Longitudinal Cohort-Based Study.

Authors:  Chien-Ting Pan; Che-Wei Liao; Cheng-Hsuan Tsai; Zheng-Wei Chen; Likwang Chen; Chi-Sheng Hung; Yu-Chen Liu; Po-Chih Lin; Chin-Chen Chang; Yi-Yao Chang; Vin-Cent Wu; Yen-Hung Lin
Journal:  J Am Heart Assoc       Date:  2020-02-19       Impact factor: 5.501

Review 6.  Oxidative Stress: A Unifying Paradigm in Hypertension.

Authors:  Rhian M Touyz; Francisco J Rios; Rhéure Alves-Lopes; Karla B Neves; Livia L Camargo; Augusto C Montezano
Journal:  Can J Cardiol       Date:  2020-02-24       Impact factor: 5.223

7.  Blocking interleukin-6 trans-signaling protects against renal fibrosis by suppressing STAT3 activation.

Authors:  Wei Chen; Hui Yuan; Wenmin Cao; Tianwei Wang; Wei Chen; Hang Yu; Yao Fu; Bo Jiang; Hong Zhou; Hongqian Guo; Xiaozhi Zhao
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

8.  Zi Shen Huo Luo Formula Enhances the Therapeutic Effects of Angiotensin-Converting Enzyme Inhibitors on Hypertensive Left Ventricular Hypertrophy by Interfering With Aldosterone Breakthrough and Affecting Caveolin-1/Mineralocorticoid Receptor Colocalization and Downstream Extracellular Signal-Regulated Kinase Signaling.

Authors:  Xiaotong Song; Yue Zhao; Shijun Wang; Yuan Wang; Qian Chen; Haijun Zhao; Hua Wang; Sheng Tian; Huayun Yu; Zhichun Wu
Journal:  Front Pharmacol       Date:  2020-04-03       Impact factor: 5.810

9.  New-Onset Atrial Fibrillation in Patients With Primary Aldosteronism Receiving Different Treatment Strategies: Systematic Review and Pooled Analysis of Three Studies.

Authors:  Cheng-Hsuan Tsai; Ya-Li Chen; Chien-Ting Pan; Yen-Tin Lin; Po-Chin Lee; Yu-Wei Chiu; Che-Wei Liao; Zheng-Wei Chen; Chin-Chen Chang; Yi-Yao Chang; Chi-Sheng Hung; Yen-Hung Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-24       Impact factor: 5.555

10.  Renin-angiotensin system inhibitor is associated with the reduced risk of all-cause mortality in COVID-19 among patients with/without hypertension.

Authors:  Huai-Yu Wang; Suyuan Peng; Zhanghui Ye; Pengfei Li; Qing Li; Xuanyu Shi; Rui Zeng; Ying Yao; Fan He; Junhua Li; Liu Liu; Shuwang Ge; Xianjun Ke; Zhibin Zhou; Gang Xu; Ming-Hui Zhao; Haibo Wang; Luxia Zhang; Erdan Dong
Journal:  Front Med       Date:  2021-07-09       Impact factor: 9.927

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.